Proteins and peptides

• Composition: Proteins consists of a chain of > 100 amino acids (AAs) that are connected through multiple peptide bonds (polypeptide chain).
  • Peptide: a chain of < 100 connected AAs
  • Peptide bond: A covalent bond (–CO–NH–) is formed when the carboxyl group (COOH) of an AA reacts with the amino group (NH2) of another AA and causes the release of an H2O molecule (also known as a condensation reaction).

• Structure: broken down into 4 levels
  • Primary: the sequence of AAs in the polypeptide chain
  • Secondary: structural folding that occurs based on patterns of H⁺-bonds between parts of the same polypeptide chain
    • E.g.: α-helix and β-sheets
  • Tertiary: 3-dimensional structure of secondary structures
  • Quaternary: 3-dimensional structure of ≥ 2 individual polypeptide chains (subunits) = multimer
  • For both tertiary and quarternary, folding driven by: hydrophobic interactions, H+-bonds, salt bridges, disulfide bonds
  • Proper protein folding must occur for a protein to be functional (see learning card on translation and protein synthesis)
• Protein synthesis: See learning card on translation and protein synthesis.
• Denaturation: the undoing of correct protein structure
  • Causes: pH changes, temperature changes, change in surrounding chemicals (oxidation, deamination, glycosylation, etc.)

References:^[1]

• Process
  1. Stomach
     • Gastric acid causes denaturation
     • Cleavage via pepsin
  2. Duodenum: further cleavage from pancreatic and intestinal proteases
  3. Enterocytes:
     1. Absorption of di-, tri-, and tetrapeptides: likely via a proton symporter
     2. Absorption of single amino acids: via Na⁺-coupled carrier proteins for specific AA groups (neutral, branched-chain, aromatic, acidic, basic)
  4. AAs enter bloodstream → liver (via portal vein)

• Proteases: enzymes that split peptide bonds via hydrolysis

• Zymogens: proteases that are first secreted in an inactive form to avoid damage to the immediate surrounding tissue
  • For example, pancreatic proteases are first secreted as inactive precursors (zymogens) before being activated in the duodenum.

Important proteases of the gastrointestinal tract
Proteases			Location	Reaction	Product
Endopeptidases: split peptide bonds within the polypeptide chain		Pepsin	Stomach	Zymogen pepsinogen activated to pepsin by gastric acid Preferably cleaves bonds involving phenylalanine, tyrosine and leucine	Peptides Oligopeptides
		Trypsin	Pancreas secretion → duodenum	Zymogen trypsinogen activated to trypsin by enteropeptidase Preferably cleaves bonds of the C-terminal of basic AAs lysine and arginine	Oligopeptides
		Chymotrypsin	Pancreas secretion → duodenum	Zymogen chymotrypsinogen activated to chymotrypsin by trypsin Preferably cleaves bonds of aromatic and large hydrophobic AAs	Oligopeptides
Exopeptidases: split peptide bonds from end AAs	Carboxypeptidases: split unspecific end AAs from C-terminal	Carboxypeptidase A	Pancreas secretion → duodenum	Activated from zymogen procarboxypeptidase A by trypsin Cleaves bonds involving aromatic AAs	AAs
		Carboxypeptidase B	Pancreas secretion → duodenum	Activated from zymogen procarboxypeptidase B by trypsin Cleaves bonds involving basic AAs	AAs
	Aminopeptidase		Intestinal mucosa	Cleaves unspecific end AAs from N-terminal	AAs
	Dipeptidase		Intestinal mucosa	Cleaves dipeptides	AAs

Trypsinogen is first activated by enteropeptidase via proteolytic cleavage at the N-terminal. The resulting trypsin then activates other zymogens, including further trypsinogen (positive feedback loop).

The inactive zymogen pepsinogen is activated to pepsin by gastric acid.

References:^{[2][3][3][4][5][6][7]}

Protein degradation

Endogenous proteins (those synthesized in cells) are degraded by proteasomes. Exogenous proteins are degraded by lysosomes.

Ubiquitin proteasome system (UPS)

• Description: Proteins are targeted via ubiquitination for degradation in proteasomes.
  • Proteasome: a barrel-like protein complex consisting of 2 units that breaks down marked proteins into peptides via ATP hydrolysis of peptide bonds
• Pathway
  1. Ubiquitination: addition of ubiquitin to the ε-amino group of lysine residues of a substrate protein; it consists of 3 parts
     1. Activation: performed by ubiquitin-activating enzymes (E1s)
     2. Conjugation: performed by ubiquitin-conjugating enzymes (E2s)
     3. Ligation: performed by ubiquitin ligases (E3s)
  2. Degradation:
     1. Polyubiquitinated proteins are recognized by proteasomes.
     2. Proteins are broken down into peptides via hydrolysis of peptide bonds.

Lysosomes

• Process
  • Foreign proteins are endocytosed into cells and form an endosome.
  • Endosomes merge with lysosomes.
  • Lysosomal hydrolases break down proteins into peptides via hydrolysis of peptide bonds.

Examples of diseases associated with aberrant proteolysis

There are many diseases associated with aberrant proteolysis; this list is not exhaustive.

• Conditions that lead to increased tissue protein breakdown
  • Chronic inflammatory diseases (e.g., rheumatoid arthritis, systemic lupus erythematosus, Sjögren disease)
  • Diabetes mellitus
• Conditions caused by increased protein breakdown
  • Emphysema and α1-antitrypsin deficiency
  • Pancreatitis and possibly resulting exocrine pancreatic insufficiency
  • Malignancy induced cachexia
    • Pro-inflammatory cytokines (e.g. IL-1, IL-6, and TNF-α) released from tumor cells induce ubiquitination and proteasomal degradation of cellular proteins; → Degradation of myosin chains in skeletal muscle cells leads to increased muscle catabolism
    • TNF-α activates the extrinsic pathway of apoptosis
• Conditions caused by accumulation of damaged or misfolded proteins/peptides (see protein misfolding in the learning card on translation and protein synthesis for more details)
  • Age-related neurological diseases/neurodegenerative diseases (e.g., Alzheimer disease, Parkinson disease, Huntington disease)
  • Prion-related conditions (e.g., Creutzfeldt-Jakob disease)
  • Amyloidosis
  • Myotonic muscular dystrophy
  • Cardiovascular diseases
  • Inflammatory responses and autoimmune diseases
  • Malignancy

References:^[8]